Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Operations: 2021-2024

Historic Cash from Operations for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$167.6 million.

  • Amylyx Pharmaceuticals' Cash from Operations rose 26.95% to -$30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.4 million, marking a year-over-year decrease of 62.43%. This contributed to the annual value of -$167.6 million for FY2024, which is 1506.55% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Cash from Operations stood at -$167.6 million, which was down 1,506.55% from $11.9 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Cash from Operations registered a high of $11.9 million during FY2023, and its lowest value of -$179.9 million during FY2022.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Cash from Operations value was -$167.6 million (recorded in 2024), while the average stood at -$111.9 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Cash from Operations skyrocketed by 106.63% in 2023 and then crashed by 1,506.55% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Cash from Operations stood at -$74.8 million in 2021, then tumbled by 140.47% to -$179.9 million in 2022, then spiked by 106.63% to $11.9 million in 2023, then tumbled by 1,506.55% to -$167.6 million in 2024.